Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative...
Read moreDetails